GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,775.00p
   
  • Change Today:
    -8.50p
  • 52 Week High: 1,812.50p
  • 52 Week Low: 1,316.00p
  • Currency: UK Pounds
  • Shares Issued: 4,144.92m
  • Volume: 9,685,447
  • Market Cap: £73,572m
  • RiskGrade: 129

US FDA accepts GSK supplemental application for Jemperli cancer drug

By Frank Prenesti

Date: Tuesday 06 Jun 2023

LONDON (ShareCast) - (Sharecast News) - GSK said the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application for its Jemperli treatment of adults with primary advanced or recurrent endometrial cancer.
If approved, the drug, also known as dostarlimab, combined with chemotherapy, "could represent the first meaningful frontline treatment advancement in decades for patients with primary advanced or recurrent endometrial cancer". the company said on Tuesday.

Endometrial cancer is the most common gynaecologic cancer in developed countries, with about 60,000 new cases every year in the US. Around 15-20% of patients will be diagnosed with advanced disease at the time of diagnosis.

Reporting by Frank Prenesti for Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,775.00p
Change Today -8.50p
% Change -0.48 %
52 Week High 1,812.50p
52 Week Low 1,316.00p
Volume 9,685,447
Shares Issued 4,144.92m
Market Cap £73,572m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
69.05% below the market average69.05% below the market average69.05% below the market average69.05% below the market average69.05% below the market average
45.1% below the sector average45.1% below the sector average45.1% below the sector average45.1% below the sector average45.1% below the sector average
Price Trend
47.89% above the market average47.89% above the market average47.89% above the market average47.89% above the market average47.89% above the market average
62.96% above the sector average62.96% above the sector average62.96% above the sector average62.96% above the sector average62.96% above the sector average
Income
2.90% above the market average2.90% above the market average2.90% above the market average2.90% above the market average2.90% above the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average
Growth
20.71% below the market average20.71% below the market average20.71% below the market average20.71% below the market average20.71% below the market average
29.41% above the sector average29.41% above the sector average29.41% above the sector average29.41% above the sector average29.41% above the sector average

What The Brokers Say

Strong Buy 8
Buy 5
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 16-May-24 22-Feb-24
Paid 11-Jul-24 11-Apr-24
Amount 15.00p 16.00p

Trades for 17-May-2024

Time Volume / Share Price
16:51 423 @ 1,775.00p
16:37 20,200 @ 1,771.97p
16:36 10,580 @ 1,775.00p
16:35 3,357,820 @ 1,775.00p
16:35 2,092 @ 1,775.00p

GSK Key Personnel

CEO Emma Walmsley

Top of Page